Ahmed O Kaseb, MD
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Education & Training
Degree-Granting Education
1996 | Cairo University School of Medicine, Cairo, EGY, MD, Medicine |
Postgraduate Training
2005-2007 | Medical Oncology Fellow, Internal Medicine, Henry Ford Hospital, Detroit, MI |
2004-2005 | Internal Medicine Staff Physician, Internal Medicine, Henry Ford Hospital, Detroit, MI |
2001-2004 | Internal Medicine Residency, Internal Medicine, Wayne State University/Detroit Medical Center, Sanai-Grace Hospital, Detroit, MI |
1999-2001 | Research Fellowship, Pediatrics and Human Genetics, University of Michigan, Ann Arbor, MI |
1998-1999 | Externship, Internal Medicine, Michigan State University, East Lansing, MI |
1997-1998 | Clinical Internship, Medicine, Cairo University Hospitals, Cairo |
Board Certifications
2007 | American Board of Medical Oncology |
2004 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Administrative Appointments/Responsibilities
Director: Hepatocellular Carcinoma Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Co-founding Chair and Steering Committee member ( supporting 18 institutes in USA/Canada), Hepatocellular Carcinoma Epidemiology Consortium (WWW.HCCEC.ORG), Houston, TX, 2022 - Present
Contact PI and Clinical PI, NCI RO1 grant in HCC ($3.9 million), Houston, TX, 2021 - 2026
Elected Member, National Hepatobiliary Task Force Committee, GI Steering Committee at NCI, Houston, TX, 2021 - 2021
Chairperson, PRCRP PAYA- Liver Cancer-1 peer review Panel, Houston, TX, 2021 - Present
Invited Member: Systemic Therapy for Hepatocellular Carcinoma Guideline Panel: to co-chair panel, Society for Immunotherapy of Cancer (SITC), Houston, TX, 2020 - Present
Study Section Member, NIH/NCI Oncology 2 – Translational Clinical IRG (OTC), Houston, TX, 2020 - 2020
Clinical PI, and Co-Director, The University of Texas MD Anderson Cancer Center SPORE grant in HCC, Houston, TX, 2019 - 2024
Invited Member: Systemic Therapy for Hepatocellular Carcinoma Guideline Panel: to co-chair panel, International Liver Cancer Association (ILCA), Houston, TX, 2019 - Present
Membership Committee, Harris County Medical Society Executive Board service, Houston, TX, 2019 - 2020
Member: Institutional Board Review, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Invited Member: Systemic Therapy for Hepatocellular Carcinoma Guideline Panel: to co-chair panel, American Society of Clinical oncology, Houston, TX, 2018 - Present
Chair, Steering Committee and Scientific Advisory Board, The University of Texas MD Anderson Cancer Center Alliance with Polaris, Houston, TX, 2018 - Present
Member, Steering Committee and Scientific Advisory Board, The University of Texas MD Anderson Cancer Center Alliance with Tvardi, Houston, TX, 2018 - Present
Founding Chair, Hepatocellular Carcinoma International Biomarkers Assessment Consortium (HIBAC): with The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Member: Educational Committee, International Liver Cancer Association (ILCA), Houston, TX, 2018 - Present
Health Care Quality Committee, Harris County Medical Society Executive Board service, Houston, TX, 2018 - 2019
Member, Executive Committee, Harris County Medical Society, Houston, TX, 2017 - 2018
Alternate Delegate to TMA, Harris County Medical Society Executive Board service, Houston, TX, 2017 - 2018
Co-Chair, Senatorial district 11, Texas Medical Association Political Action Committee (TexPAC), Houston, TX, 2017 - Present
Chair, Council of International and Affiliated Medical Societies, Harris County Medical Society, Houston, TX, 2017 - 2018
US AID Grants Review Panel Member, U.S.-Egypt Science and Technology Joint Fund, Keck Center of the National Academies of Sciences, Engineering, and Medicine, Houston, TX, 2017 - 2020
Study Section Member, Liver Cancer panel at Department of Defense, United States, Houston, TX, 2017 - 2019
Editor-in-Chief, Journal of Hepatocellular Carcinoma (2020 Impact Factor: 5.828, 5-year Impact: 6.783), Houston, TX, 2013 - Present
Member: Clinical Research Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2018
Member: Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2016
Leader: Comprehensive Cancer Control Initiative (HCC), The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2020
Disease Site Liaison: for the Gastrointestinal Center: International Patient Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2019
Founder and Director: Black Seed Research Group, University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Founder and Director: Hepatocellular Carcinoma Interdisciplinary Research Group (HIRG), The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Other Appointments/Responsibilities
Founder, Director, Hepatocellular Carcinoma Interdisciplinary Research Group (HIRG), Houston, TX, 2009 - Present
Endowed Positions
John E. and Dorothy J. Harris, Department of Gastrointestinal (GI) Medical Oncology - Research, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, 2022 - Present
Honors & Awards
2006 | ASCO Foundation Merit Award, American Society of Clinical Oncology |
2006 | Basic Research Presentation Merit Award, 13th Annual Research Forum of Henry Ford Health System |
2005 | ACP Merit Award, American College of Physicians |
2004 | ACP Merit Award, American College of Physicians |
2004 | Best Ambulatory Resident Award, Sinai-Grace Hospital/Wayne State University |
1990 | The Egyptian Government Award, Egypt |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume. JNCI Cancer Spectr. e-Pub 2024. PMID: 38730548.
- Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol:JCO2302745. e-Pub 2024. PMID: 38502889.
- Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. medRxiv, 2024. e-Pub 2024. PMID: 38559070.
- Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. JHEP Rep 6(2):100982, 2024. e-Pub 2023. PMID: 38274490.
- Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. e-Pub 2024. PMID: 38364832.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America. Hepatology. e-Pub 2024. PMID: 38381705.
- Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. e-Pub 2024. PMID: 38270822.
- Maen A, Gok Yavuz B, Mohamed YI, Esmail A, Lu J, Mohamed A, Azmi AS, Kaseb M, Kasseb O, Li D, Gocio M, Kocak M, Selim A, Ma Q, Kaseb AO. Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Front Pharmacol 15:1291212, 2024. e-Pub 2024. PMID: 38379905.
- Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
- Yalcin S, Lacin S, Kaseb AO, Peynircioglu B, Cantasdemir M, Çil BE, Hurmuz P, Dogrul AB, Bozkurt MF, Abali H, Akhan O, Simsek H, Sahin B, Aykan FN, Yücel I, Tellioglu G, Selçukbiricik F, Philip PA. A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements. J Hepatocell Carcinoma 11:953-974, 2024. e-Pub 2024. PMID: 38832120.
- Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. ASO Visual Abstract: Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol 30(13):8019-8020, 2023. PMID: 37782416.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. PMID: 38085001.
- Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. e-Pub 2023. PMID: 38159256.
- Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatol Commun 7(11), 2023. e-Pub 2023. PMID: 37889520.
- Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S, Cheah YL, Simon CJ, Noureddin M, Connor A, Saharia A, Moore LW, Heyne K, Kaseb AO, Gaber AO, Ghobrial RM. Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers (Basel) 15(22), 2023. e-Pub 2023. PMID: 38001597.
- Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 14(1):7621, 2023. e-Pub 2023. PMID: 37993437.
- Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 15(11):1900-1912, 2023. PMID: 38077640.
- Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH, IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. e-Pub 2023. PMID: 37871608.
- Lee MS, Kaseb AO, Pant S. The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers. Clin Cancer Res, 2023. PMID: 37092904.
- Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol. e-Pub 2023. PMID: 37679537.
- Chamseddine S, LaPelusa M, Kaseb AO. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444618.
- Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. e-Pub 2023. PMID: 37467732.
- Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A, CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. e-Pub 2023. PMID: 37499670.
- Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. e-Pub 2023. PMID: 37268830.
- George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM. Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol 16(1):61, 2023. e-Pub 2023. PMID: 37312210.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Guevara EY, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. Am J Gastroenterol. e-Pub 2023. PMID: 37307533.
- Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A 120(19):e2300706120, 2023. e-Pub 2023. PMID: 37126700.
- El-Serag HB, Ward JW, Asrani SK, Singal AG, Rich N, Thrift AP, Deshpande S, Turner BJ, Kaseb AO, Harrison AC, Fortune BE, Kanwal F. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol 21(9):2183-2192. e-Pub 2023. PMID: 37086825.
- Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int 43(3):695-707, 2023. e-Pub 2023. PMID: 36577703.
- Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist. e-Pub 2023. PMID: 36952233.
- Kothari AN, Massarweh NN, Flitcroft MA, Newhook T, Tzeng CD, Chun YS, Kaseb AO, Vauthey JN, Tran Cao HS. Evaluating the benefit of surgical resection for hepatocellular carcinoma with multifocality or intrahepatic vascular invasion. HPB (Oxford) 25(7):758-765. e-Pub 2023. PMID: 37085394.
- Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Sci Data 10(1):33, 2023. e-Pub 2023. PMID: 36653372.
- Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Front Oncol 13:1128569, 2023. e-Pub 2023. PMID: 36865801.
- Omar A, Kaseb A, Elbaz T, El-Kassas M, El Fouly A, Hanno AF, El Dorry A, Hosni A, Helmy A, Saad AS, Alolayan A, Eysa BE, Hamada E, Azim H, Khattab H, Elghazaly H, Tawfik H, Ayoub H, Khaled H, Saadeldin I, Waked I, Barakat EMF, El Meteini M, Hamed Shaaban M, EzzElarab M, Fathy M, Shaker M, Sobhi M, Shaker MK, ElGharib M, Abdullah M, Mokhtar M, Elshazli M, Heikal OMK, Hetta O, ElWakil RM, Abdel Wahab S, Eid SS, Rostom Y, Egyptian Liver Cancer Committee Study Group. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma. J Hepatocell Carcinoma 10:1547-1571, 2023. e-Pub 2023. PMID: 37744303.
- Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 13(1):7477, 2022. e-Pub 2022. PMID: 36463294.
- Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13:1314-1321, 2022. e-Pub 2022. PMID: 36473155.
- Mohamed A, Azmi AS, Asa SL, Tirumani SH, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Kaseb AO. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Curr Oncol 29(11):9018-9030, 2022. e-Pub 2022. PMID: 36421360.
- Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 9:1065-1079, 2022. e-Pub 2022. PMID: 36254201.
- Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol 12:986305, 2022. e-Pub 2022. PMID: 36276070.
- Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 23(8):995-1008, 2022. e-Pub 2022. PMID: 35798016.
- Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Sci Rep 12(1):14449, 2022. e-Pub 2022. PMID: 36002545.
- Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 6(7):1776-1785, 2022. e-Pub 2022. PMID: 35481940.
- Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. e-Pub 2022. PMID: 35739268.
- Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76(4):862-873, 2022. e-Pub 2021. PMID: 34902530.
- Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
- McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 22(3):823-832, 2022. e-Pub 2021. PMID: 34856069.
- Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406533.
- Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, Kumar SV, Shin JH, Choi YR, Shim JJ, Kim H, Kim J, Kim S, Guo S, Johnson RL, Kaseb A, Kang KJ, Chun YS, Jang HJ, Lee BG, Woo HG, Ha MJ, Akbani R, Roberts LR, Wheeler DA, Lee JS. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. e-Pub 2022. PMID: 35349735.
- Lee SH, Jeong YS, Lee S, Sohn BH, Hwang HK, Choi GH, Kang CM, Choi JS, Lee WJ, Cheong JH, Jang HJ, Kaseb A, Roberts L, Yim SY, Chun YS, Lee JS. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Commun (Lond) 42(2):179-183, 2022. e-Pub 2022. PMID: 35032367.
- Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med 27(73):267-278, 2022. e-Pub 2021. PMID: 34606324.
- Abdelsalam ME, Figueira TMA, Ensor J, Tam AL, Avritscher R, Kaseb A, Gupta S. The Impact of the Use of C-Arm Cone-Beam CT During Chemoembolization for Hepatocellular Carcinoma. Curr Med Imaging 18(4):372-380, 2022. PMID: 34420509.
- Abdelrahim M, Esmail A, Al Saadi N, Zsigmond E, Al Najjar E, Bugazia D, Al-Rawi H, Alsaadi A, Kaseb AO. Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Front Pharmacol 13:848676, 2022. e-Pub 2022. PMID: 35462919.
- Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 9:823-837, 2022. e-Pub 2022. PMID: 35996397.
- Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U. The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. J Hepatocell Carcinoma 9:913-927, 2022. e-Pub 2022. PMID: 36065424.
- Wang Z, Kaseb AO, Amin HM, Hassan MM, Wang W, Morris JS. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. J Am Stat Assoc 117(538):533-546, 2022. e-Pub 2022. PMID: 36090952.
- Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008350.
- Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181, 2021. PMID: 35068861.
- Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 157:140-152, 2021. e-Pub 2021. PMID: 34508996.
- Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer 10(6):583-592, 2021. e-Pub 2021. PMID: 34950181.
- Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med 10(20):7308-7319, 2021. e-Pub 2021. PMID: 34535983.
- Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 9(9), 2021. PMID: 34518290.
- Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study. Hepatology. e-Pub 2021. PMID: 34233041.
- Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
- Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1195-1207, 2021. e-Pub 2021. PMID: 34595140.
- Lithy RM, Elbaz T, H Abdelmaksoud A, M Nabil M, Rashed N, Omran D, Kaseb AO, O Abdelaziz A, I Shousha H. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. Eur J Gastroenterol Hepatol. e-Pub 2020. PMID: 33208688.
- Kaseb A, Xiao L, Hassan MM, Abbruzzese JL, Cheung S, Mohamed H, Vierling J, Jalal P, Lee J-S, Wallace MJ, Vauthey J-N, Aloia TA, Curley SA, Rashid A, Morris J. Development and Validation of a modified Child-Turcotte-Pugh score to predict survival in patients with hepatocellular carcinoma. J Clin Oncol. e-Pub 2016.
- Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging 39(5):1070-87, 2014. e-Pub 2014. PMID: 24695938.
- Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22, 2014. PMID: 24931142.
- Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
- Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology 86(2):63-71, 2014. e-Pub 2014. PMID: 24401634.
- Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am 93(6):1423-50, 2013. PMID: 24206860.
- Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 3(4):344-8, 2013. e-Pub 2012. PMID: 24674408.
- Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. Oncology 85(4):197-203. e-Pub 2013. PMID: 24051705.
- Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 119(18):3334-42. e-Pub 2013. PMID: 23821538.
- Frenette CT, Boktour M, Burroughs SG, Kaseb A, Aloia TA, Galati J, Gaber AO, Monsour H, Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int 26(7):734-9, 2013. e-Pub 2013. PMID: 23701126.
- Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog. e-Pub 2013. PMID: 23776098.
- Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 5(6):332-5, 2013. PMID: 23805358.
- Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res 190:247-59, 2013. PMID: 22941025.
- Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-162, 2013. e-Pub 2013. PMID: 23847722.
- Kaseb AO. Beyond the Basics: The Differential Effects of Demographics and Hepatitis Status on Treatment Outcome in Hepatocellular Carcinoma. Oncology 85(1):41-43, 2013. e-Pub 2013. PMID: 23838536.
- Shindoh J, Kaseb A, Vauthey JN. Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. Liver Cancer 2(1):47-54, 2013. PMID: 24159596.
- Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev 14(11):6721-6, 2013. PMID: 24377595.
- Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial. Oncology 82(2):67-74, 2012. e-Pub 2012. PMID: 22327795.
- Mahale P, Kaseb A, Davila M, Torres HA. The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C viremia. Oncologist 17(9):e21-3, 2012. PMID: 23002170.
- Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-8, 2011. e-Pub 2011. PMID: 21793641.
- Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-9, 2011. e-Pub 2011. PMID: 21911725.
- El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 2011. e-Pub 2010. PMID: 20107864.
- Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. Oncology 80(5-6):373-381, 2011. e-Pub 2011. PMID: 21822028.
- Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. e-Pub 2010. PMID: 21157958.
- Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 2010. PMID: 20166205.
- Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 115(21):4895-906, 2009. PMID: 19637355.
- Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69(13):5575-83, 2009. e-Pub 2009. PMID: 19549912.
- Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49(5):1563-70, 2009. PMID: 19399911.
- Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145(4):399-405, 2009. PMID: 19303988.
- Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 50(2):334-41, 2009. e-Pub 2008. PMID: 19070394.
- Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843-50, 2009. e-Pub 2009. PMID: 19139433.
- Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 123(8):1883-91, 2008. PMID: 18688864.
- Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67(16):7782-8, 2007. PMID: 17699783.
- Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 104(7):2343-8, 2007. e-Pub 2007. PMID: 17283334.
- Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwally A, Khaled H, Kurnit DM. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102(21):7683-8, 2005. PMID: 15914551.
Editorials
- Wilson SR, Greig P, Kaseb AO. Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 12(5):300-1, 2010. PMID: 20590902.
Abstracts
- Masatoshi Kudo, Minshan Chen, Pierce K. H. Chow, Ahmed Omar Kaseb, Han Chu Lee, Adam C. Yopp, Lars Becker, Sairy Hernandez Painter, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Journal of Clinical Oncology 41(16):4002-4002, 2023. e-Pub 2023.
- Li Gu, Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang, Shusil K. Pandit, Shadi Chamseddine, Lianchun Xiao, Yehia I. Mohamed, Ahmed O. Kaseb, Michael Karin and Shabnam Shalapour. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. PNAS 120(19), 2023. e-Pub 2023.
- Ahmed W. Moawad, Ali Morshid, Ahmed M. Khalaf, Mohab M. Elmohr, John D. Hazle, David Fuentes, Mohamed Badawy, Ahmed O. Kaseb, Manal Hassan, Armeen Mahvash, Janio Szklaruk, Aliyya Qayyum, Abdelrahman Abusaif, William C. Bennett, Tracy S. Nolan, Brittney Camp & Khaled M. Elsayes. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Scientific data 10(33), 2023.
Book Chapters
- Hassan M, Kaseb A. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Springer, 1-19, 2010.
- Kaseb A, Thomas M, Curley S. Gall Bladder and Bile Duct Cancer. In: Holland-Frei Cancer Medicine. 8. People's Medical Publishing House-USA: Shelton, CT, Part Five, Section 27; 87, 2009.
- Kaseb A, Selim Abdel-Hafez. Kalonji (Thymoquinone). In: Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. World Scientific Publishing Co., Inc: Hackensack, 257-280, 2009.
- Kaseb A, Thomas M. Chemotherapy and Novel Therapies. In: Hepatocellular Carcinoma: A Practical Approach. Informa Health Care Publishing Co., Inc: United Kingdom, 2008.
- Azmi AS, Mohammad M, Kaseb A, Sarkar F, Mohammad RM. Utility of Animal Models in Pancreatic Cancer Research. In: Pancreatic Cancer. Springer: New York, NY, 577-599, 2008.
- Kaseb A, Tejwani S. Vaccines in Medical Oncology. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier Publishing Co., Inc, 2006.
- Kaseb A, Tejwani S. Biological Response Modifiers in Cancer Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006.
- Kaseb A, Tejwani S. Cancer Gene Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006.
- Kaseb A, Thomas M. The Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Humana Press.
Letters to the Editor
- Kaseb AO, Morris JS, Hassan MM, Abbruzzese JL. Reply to A. Goyal et al. J Clin Oncol 30: 1019-1020, 2012.
Grant & Contract Support
Title: | Early Therapeutics Development with Phase II Emphasis |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | A Phase III Randomized, Placebo Controlled, Double-Blind Trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First-line systemic Treatment of Hepatocellular Carcinoma (HCC) |
Funding Source: | SEARCH |
Role: | Principal Investigator |
Title: | A Phase II Trial of Erlotinib plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy |
Funding Source: | N/A |
Role: | Principal Investigator |
Title: | A Randomized, Double-Blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma |
Funding Source: | N/A |
Role: | Principal Investigator |
Title: | Glypican in Hepatocellular Carcinoma |
Funding Source: | Chugai |
Role: | Co-Principal Investigator |
Title: | Prognostic Factors in Hepatocellular |
Funding Source: | Bayer-Onyx |
Role: | Co-Principal Investigator |
Title: | Early Therapeutics Development with Phase II Emphasis (PP-20) |
Funding Source: | N/A |
Role: | Co-Principal Investigator |
Title: | A Phase II Study Trastuzumab (NSC 688097) in Her2/neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756) |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | A Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients with Advanced Primary Cancers of the Liver, including Hepatocellular Carcinoma (HCC) and Carcinoma of the Gallbladder or Biliary Tract (BTC) (P01-05-23) |
Funding Source: | N/A |
Role: | Principal Investigator |
Title: | Co-Principal Investigator, A Phase III Randomized, Double-Blind, Placebo Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma after Surgical Resection or Local Ablation |
Funding Source: | N/A |
Role: | Co-Principal Investigator |
Title: | A Phase II Study of Yttrium-90 Microspheres (SIR-Spheres) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma |
Funding Source: | N/A |
Role: | Co-Principal Investigator |
Title: | A Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors |
Funding Source: | N/A |
Role: | Co-Principal Investigator |
Title: | Novel Point-of-Care Tool to Predict REsponse to Sorafenib in Hepatocellular Carcinoma |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | A Phase II study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | A Phase II Trial of Erlotinib plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy, 2009-0260 |
Funding Source: | N/A |
Role: | Principal Investigator |
Title: | Randomized phase III trial of sorafenib vs. stereotactic body radiation therapy followed by sorafenib in HCC |
Funding Source: | RTOG |
Role: | Co-Principal Investigator |
Title: | |
Funding Source: | NIH/NCI |
Role: | Principal Investigator-MDACC |
Title: | Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Novel point-of-care tool to predict response to sorafenib in hepatocellular carcinoma |
Funding Source: | SINF-MDACC |
Role: | Principal Investigator |
Title: | HCC Virtual Tumor Board |
Funding Source: | Bay Inc. Research Grant |
Role: | Principal Investigator |
Title: | The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | An oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC) |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | PA18-0950 REFINE: Regorafenib observational study in hepatocellular carcinoma |
Funding Source: | BAYER HEALTHCARE PHARMACEUTICALS |
Role: | Principal Investigator |
Title: | SIV: Phase I trial evaluating genetically modified autologous T cells expressing a Tcell receptor recognizing a cancer/germline antigen in patients with solid tumors including but not limited to non-small cell lung cancer or hepatocellular carcinoma |
Funding Source: | Immatics US INC |
Role: | Principal Investigator |
Title: | A Phase III, Open-Label, Randomized Study in Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
Funding Source: | Genentech |
Role: | Principal Investigator |
Title: | An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumba Plus Ipilumumab (Anti-CTLA-4 Antibody) in Patients with Resectable and Potentially Rescectable HCC |
Funding Source: | Bristol Myers Squibb (BMS) |
Role: | Principal Investigator |
Title: | Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma - 5R21EB026089 |
Funding Source: | NIH/NIBIB |
Role: | Principal Investigator |
Title: | Diet and the gut microbiome in hepatocellular carcinoma patients initiating immunotherapy: new targets to improve clinical outcomes |
Funding Source: | NIH/NCI |
Role: | Multiple Principal Investigator |
Title: | 2018-0516: A Phase I Open-Labeled Clinical Trial Evaluating The safety and Anti-Tumor Activity of Autologus T Cells Expressing Enhanced TCRs Specific for Alpha-feroprotein in HLA-A2 positive subjects with Advance Hepatocellular Carcinoma (HCC) |
Funding Source: | Adaptimmune LLC |
Role: | Principal Investigator |
Title: | 2019-1014: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (ANTI-PD-L1 ANTIBODY) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation |
Funding Source: | Genentech |
Role: | Principal Investigator |
Title: | 2017-0904: Phase I trial evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with hepatocellular carcinoma |
Funding Source: | ACTengube |
Role: | Principal Investigator |
Title: | 2020-0791: An Open-label, Phase II, Pre-operative Atezolizumab plus Bevacizumab for Resectable Hepatocellular Carcinoma |
Funding Source: | Genentech |
Role: | Principal Investigator |
Title: | 2019-0569: A Phase 1-2 Study of ABX196 in Combination with Nivolumab in Patients with Hepatocellular Carcinoma |
Funding Source: | Abivax |
Role: | Principal Investigator |
Title: | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Overcoming barriers to immune checkpoint inhibition in advanced hepatocellular carcinoma by molecularly targeted photothermal ablation |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC) |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Transcatheter Chemistry: A Novel Approach In Image-Guided Therapy |
Funding Source: | NIH/NCI |
Role: | OSC |
Title: | Molecular glues for treatment of liver cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | OSC |
Title: | Phase II and Biomarker Study of Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan |
Funding Source: | Methodist Hospital Research Institution |
Role: | Principal Investigator |
Title: | Metabolism-Mediated Resistance to Ferroptotic Cell Death in Liver Cancer |
Funding Source: | NIH/NCI |
Role: | OSC |
Title: | A phase II and biomarker study of targeting GHR/PD-L1/CTLA-4 in unresectable hepatocellular carcinoma |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |